Celularity Inc.
CELUDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CELU's past catalysts played out
PDA-002
Diabetic Nephropathies
CYNK-001
Coronavirus
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Crohn's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PDA-002 | Phase 2 | Diabetic Nephropathies | - | - |
CYNK-001 | Phase 2 | Coronavirus | - | - |
Human Placenta-Derived Cells PDA001 Intravenous Infusion | Phase 2 | Crohn's Disease | - | - |
Frequently asked questions
What is in Celularity Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Celularity Inc.'s (CELU) pipeline across Phase 2. Its lead program is PDA-002 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celularity Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Celularity Inc. (CELU) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CELU biotech catalysts?→
Add CELU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celularity Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.